RE:This is just soooo uglyboazklinghorn wrote: The price action continues to be super scary as we wait endlessly for 3Q numbers. I wonder if Gilles or Ronnie will address their shareholders at some point. HaHaHa no i don't they are all snuggled up somewhere in Eastern Canada probably already on Christmas break. #oldmanpower
Doesn't look pretty. I don't know how long in advance a large order is placed but you'd think CZO would get 30-60-90 days notice. Are we into bookings for Q1 2024 now? If the order isn't being filled in Q4 hopefully the order is in place for Q1 2024. Next Gilles said the preservative free, powder beta glucan is expected to be launched "very, very soon" with Symrise in his October presentation allowing CZO to reach new markets. How does this impact sales/margins near-term. CZO is also working on an avenanthramide powder. The avenanthramide malting technology for the neutraceutical market appears at commercial volumes and able to produce what four plants could from the same input based on Gilles presentation. Is there demand lined up for 2024? The first patient for the avenanthramide pill clinical trial should be dosed imminently. Does anything make CZO's pill special beyond being pharma-grade, etc., and the dosing? Is there preclinical data supporting superiority to what's been done before? We've seen no data. Is CZO's formulation slow-release? How stong is the case for use against COVID heart inflammation given that appears to be the patient group CZO is targeting for Phase IIa. CZO has also talked about combining avenanthramide with a newer PGX carrier. What is the ultimate game-plan and is there data to support it. Data readouts from the clinical trial may happen quickly after administration given what's said at the clinicaltrials.gov website. How long until we hear about the metrics? Safety is an issue with colchicine which is now approved by the FDA for inflammation/heart disease. Lastly, is the 5X scale-up PGX plant on time and on budget for the end of the year? There's only about one month until the end of the year given the holidays. We don't want time and cost overruns; especially if CZO's base business is suffering uncertainty. Given the agreement just signed with NATEX for the 10X scale-up the 5X scale-up should be on schedule for commissioning in Q1 2024. The timeline for the end of the year was reaffimed in the last news release. CZO also mentioned that the facility at the University of Alberta would be used for certain opportunities under discussion. What other opportunities are under discussion? With the 5X scale-up plant completed and commissioned in Q1 2024 and industry leader NATEX advancing the 10X scale-up with 50% of the infrastructure and equipment in place are licensing deals now red hot. CZO is on the path to commercialization and industrialization of PGX.